<DOC>
	<DOC>NCT01354171</DOC>
	<brief_summary>This is a multi-centre, prospective, randomized phase III trial to determine if multi-parametric Magnetic Resonance Imaging (MRI) can improve selection of patients eligible for active surveillance through better detection of clinically significant cancer.</brief_summary>
	<brief_title>Active Surveillance Magnetic Resonance Imaging Study</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>histological confirmation of adenocarcinoma of the prostate candidate for active surveillance (favourable risk prostate cancer) as defined by the following: Clinical stage T1b, T1c, T2a or T2b at the time of diagnosis Clinical (diagnostic biopsy) Gleason sum &lt; 6 PSA &lt; 10.0 ng/ml (ug/L) Previous treatment for prostate cancer including surgery (excluding biopsy), radiation therapy, hormonal therapy (e.g. megestrol, medroxyprogesterone, cyproterone, DES), glucocorticoids (except inhaled or topical), LHRH analogues (e.g. Leuprolide, goserelin), ketoconazole, nonsteroidal antiandrogens (e.g. bicalutamide, flutamide) and/or any 5Î±reductase inhibitors within 3 months of randomization Planned antiandrogen therapy Inability to undergo TRUS biopsy Inability to undergo multiparametric MRI</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>active surveillance</keyword>
	<keyword>low risk prostate cancer</keyword>
</DOC>